Condition
Hyperinsulinemia
ClinicalTrials.gov condition label
Clinical trials
19 shownEffect of Insulin Lowering on LipogenesisNCT07403604 · 2026-07-01
RECRUITINGGraded Insulin Suppression Test P&FNCT06592261 · 2024-09-16
RECRUITINGClinical and Molecular Characteristics of Primary Aldosteronism in BlacksNCT03374215 · 2017-12-14
RECRUITINGHuman Models of Selective Insulin Resistance: Pancreatic ClampNCT06558422 · 2027-01-01
NOT_YET_RECRUITINGApplication of FreeStyle Libre 2 for Evaluating Glycemic Variability Characteristics in Patients With Extreme Glucose Metabolism PhenotypesNCT07564518 · 2026-05-25
NOT_YET_RECRUITINGDiazoxide Suppression Test P&F StudyNCT06606327 · 2024-10-23
TERMINATEDPancreatic Clamp in NAFLDNCT05724134 · 2023-08-29
COMPLETEDGlycemic Effect of Diazoxide in NAFLDNCT05729282 · 2023-08-01
COMPLETEDHyperinsulinemia in Prediabetes Mediated by Interleukin-1βNCT05854251 · 2023-06-15
COMPLETEDEffect of Alpelisib in Healthy VolunteersNCT05733455 · 2023-05-09
COMPLETEDA Cold Physical Treatment to Manage Insulin ResistanceNCT02852759 · 2016-07-01
COMPLETEDReprometabolic Syndrome Mediates Subfertility in ObesityNCT02653092 · 2016-06-01
ACTIVE_NOT_RECRUITINGEMPOWIR:Enhance the Metabolic Profile of Women With Insulin ResistanceNCT00618072 · 2008-01-01
COMPLETEDMetabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose ToleranceNCT00667498 · 2004-03-01
COMPLETEDEffects of a Comprehensive Weight Management Program on Obese Adolescents and ChildrenNCT00409422 · 2002-05-01
COMPLETEDMetformin to Treat Obesity in Children With Insulin ResistanceNCT00005669 · 2000-05-01
COMPLETEDHealth Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 DiabetesNCT00005760 · 2000-05-01
COMPLETEDNatriuretic Peptides and Metabolic Risk in ObesityNCT02642523
WITHDRAWNMetformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat AbnormalitiesNCT00015691
COMPLETEDCommon interventions
PlaceboDRUG520% D-glucose (aq)DRUG2Diazoxide oral suspension, 2 mg per kg per doseDRUG2FreeStyle Libre ProDEVICE2GlucagonDRUG2Growth Hormone, HumanDRUG2Harvard Apparatus PHD ULTRA CP syringe pumpDEVICE2InsulinDRUG2Insulin humanDRUG2Octreotide AcetateDRUG2Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate AnalyzerDEVICE2[1-13C1] sodium acetateDIAGNOSTIC_TEST1[6,6-2H2] D-glucoseDIAGNOSTIC_TEST1[6,6-2H2] D-glucoseOTHER1Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)DRUG1AnakinraDRUG1BOOST PlusDIETARY_SUPPLEMENT1BOOST Plus nutritional beverageDIETARY_SUPPLEMENT1CORE BarDIETARY_SUPPLEMENT1Deuterated water (2H2O/D2O)DRUG1Deuterated water (2H2O/D2O), 70%DRUG1DextroseDRUG1Dextrose 20 % in WaterDRUG1Diazoxide oral suspension, 1 mg per kg per doseDRUG1Diazoxide, 3 mg/kg per doseDRUG1
Leading sponsors
Columbia University7Yale University2Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1First Affiliated Hospital Xi'an Jiaotong University1Jack Yanovski, M.D.1National Institute of Allergy and Infectious Diseases (NIAID)1National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1New York Medical College1Peking University People's Hospital1University Hospital, Basel, Switzerland1University of Colorado, Denver1Vanderbilt University Medical Center1
Trial status mix
COMPLETED11
RECRUITING3
NOT_YET_RECRUITING2
ACTIVE_NOT_RECRUITING1
TERMINATED1
WITHDRAWN1
Phase mix
PHASE17
NA4
PHASE23
EARLY_PHASE11
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.